Targets › AVP
1 program from 1 company in 1 trial: 1 Phase 3; Metabolic and endocrine.
Precursor of Arg-vasopressin, an antidiuretic hormone, and neurophysin 2, its carrier protein..; FUNCTION: [Arg-vasopressin]: Has a direct antidiuretic action on the kidney, it also causes vasoconstriction of the peripheral vessels. Acts by binding to vasopressin receptors (V1bR/AVPR1B, V1aR/AVPR1A, and V2R/AVPR2)..; FUNCTION: [Neurophysin 2]: Carrier protein that binds to and transports Arg-vasopressin from the…. (UniProt, P01185)
Open in Phaseline: the race on AVP, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Assistance Publique - Hôpitaux de Paris | Arginine-vasopressin (AVP) Vasopressin V1 and V2 receptor agonist | AVP | Phase 3 | Postresuscitation Syndrome | – |
Postresuscitation Syndrome (1)
small molecule (1)
Assistance Publique - Hôpitaux de Paris (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.